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I
n an accompanying Perspectives article, Cryer (1)
identiﬁes a number of different areas where thera-
peutic interventions have the potential to reduce
hypoglycemia without compromising glycemic con-
trol. Some approaches provide well-deﬁned clinical bene-
ﬁts, a few offer dramatic reductions in hypoglycemia but
remain out of reach for most people, and others, although
promising, have yet to be properly evaluated (Table 1).
In this Perspectives article, I examine the evidence that
underpins these interventions. It is beyond the scope of
this article to review the data for each potential interven-
tion in detail, but the reader is directed to the source
where appropriate. The focus of this article is treatment of
type 1 diabetes, as most of the speciﬁc potential therapies
have been evaluated in this group, although included are
comments in relation to recent trials of intensive therapy
in type 2 diabetes.
PREVENTING ABSOLUTE OR RELATIVE INSULIN
EXCESS
Education and skills training in self-management.
Long before the beneﬁts of tight glucose control had been
established (2), the belief that insulin therapy should be
designed to replace insulin “physiologically” had been
advocated by a small number of enthusiastic clinicians.
The advent of blood glucose monitoring in the late 1970s
had a major impact, since background and meal-related
insulin could be given separately and adjusted according
to self-monitored blood glucose measurements. Partici-
pants were encouraged to eat freely, calculating their
insulin dose according to their chosen amount of
carbohydrate.
Integrating these components was a complex task,
probably beyond that of many physicians, let alone pa-
tients. If this was to be undertaken every day, then patients
needed to acquire the skill of ﬂexible insulin self-manage-
ment and apply it successfully. The therapeutic education
approach was pioneered by Assal et al. (3), and Berger and
Mu ¨hlhauser (4) went on to develop a residential training
course (Insulin Treatment and Training program [ITTP])
evaluating the intervention in a series of studies, including
randomized controlled trials. Their group highlighted the
major differences between rates of severe hypoglycemia in
different centers in the Diabetes Control and Complica-
tions Trial (DCCT) and suggested that these might have
reﬂected a failure to train patients to undertake intensive
self-management safely (5).
Their data, which involve a large evaluated roll-out,
suggest that it is possible to improve and sustain glycemic
control, comparable with the DCCT ﬁndings using conven-
tional insulin while reducing rates of severe hypoglycemia
(Fig. 1) (6,7). Different deﬁnitions of hypoglycemia prevent
a detailed comparison between these and other studies,
but their principle argument that no one should embark on
intensive insulin therapy and aim for tight glucose targets
without acquiring appropriate self-management skills is
compelling. Even in countries where such training is fairly
established (7,8), relatively few adults with type 1 diabetes
appear to have undertaken validated courses in intensive
insulin self-management.
Other programs have been developed to train patients
speciﬁcally to recognize both high and low glucose values,
although most interest has centered around the ability of
patients to identify impending hypoglycemia. Blood glu-
cose awareness training, developed by Cox et al. (9) at the
University of Virginia, seeks to train patients with type 1
diabetes to improve estimation of their blood glucose
based on recognition of external cues and the known
pathophysiological changes associated with autonomic
and neuroglycopenic responses to hypoglycemia. Partici-
pants also receive feedback on their glucose estimations.
The approach shares several features with the ITTP train-
ing of the Du ¨sseldorf group and has also been extensively
evaluated. Trials led by the investigators have demon-
strated prevention of a blunted counterregulatory re-
sponse during intensiﬁcation of insulin therapy (10) and an
improved ability to estimate blood glucose that is main-
tained over some years with fewer severe hypoglycemic
events (11).
In summary, there is a reasonable body of evidence
demonstrating that high-quality skills training in insulin
self-management involving accredited educators leads to
improved glycemic control without increasing severe hy-
poglycemia. Speciﬁc programs appear particularly beneﬁ-
cial to those with hypoglycemic problems.
Improved insulin delivery in routine care. The limita-
tions of subcutaneous insulin delivery have been well
recognized ever since its discovery. The intermittent injec-
tion of insulin into subcutaneous tissue produces insulin
proﬁles that, while able to control blood glucose sufﬁ-
ciently to relieve symptoms and prevent ketosis, are far
from physiological. The advent of recombinant DNA tech-
nology in the 1980s prompted the pharmaceutical industry
to engineer different structures of the insulin molecule to
address the limitations of subcutaneous insulin delivery
(12).
The tendency of insulin molecules of conventional ani-
mal structure to aggregate in crystalline solution delays its
absorption. Transposing or substituting amino acids pro-
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The molecules remain monomeric at high concentration,
and their more rapid absorption results in a more physio-
logical insulin proﬁle. Yet the clinical advantages of quick-
acting insulin analogs over conventional insulin have
generally been modest in clinical trials, both in lowering
A1C and reducing hypoglycemia, and some have con-
cluded that they offer little additional beneﬁt (14). Never-
theless, there is reasonable evidence reporting reduced
nocturnal hypoglycemic risk when using rapid-acting in-
sulin analogs in those with well-controlled type 1 diabetes
(15,16), an outcome not included in the recent Cochrane
review (14).
The other main pharmacokinetic limitation of conven-
tional insulin delivery has also been addressed. Human
NPH insulin exhibits considerable inter- and intra-individ-
ual variability in part due to the necessity of resuspension
before injection. This, plus a pronounced peak of action
around 6–8 h after injection, contributes to the risk of
nocturnal hypoglycemia. Insulin manufacturers have tried
to solve these problems in ingenious ways. Insulin glargine
(Lantus), a diarginyl insulin analog, is a soluble insulin at
an acid pH and crystallizes in the more alkaline subcuta-
neous environment (13). Insulin detemir (Levemir) has
been constructed by adding a myristoyl fatty acid side
chain at the COOH-terminus of the B-chain, which causes
the insulin to bind to albumin (13). Both insulins have a
more prolonged action than NPH, and a reduced peak, and
provide a more physiological free insulin proﬁle with the
potential to lower rates of hypoglycemia. Yet, as with
rapid-acting insulin analogs, the major pharmacokinetic
differences compared with NPH insulin are not in general
reﬂected in the clinical trial data.
Beneﬁts of long-acting insulin analogs have been modest
in both types of diabetes with little if any difference in
glycemic control and only slight reductions in hypoglyce-
mia, mostly at night (17). The combination of both long-
and short-acting insulin analogs leads to signiﬁcant albeit
minor reductions in both A1C and hypoglycemia in adults
with type 1 diabetes (18,19).
A major difﬁculty in interpreting the mountain of data
regarding insulin treatment is that the limitation of its
delivery is just one of many factors determining glycemic
control and the risk of hypoglycemia. Thus, regulatory
clinical trials may underestimate the potential beneﬁt
because they rarely recruit highly motivated individuals
who are expert at self-managing their diabetes and can
best utilize the pharmacokinetic advantages. Regulatory
trials may also favor conventional insulins because clinical
experience with the newer insulins is often necessary to
establish the most effective combination and timing of
injection. However, because asymptomatic nocturnal hy-
poglycemia may contribute to the generation of hypogly-
cemia unawareness (20), such insulins should be offered
to those skilled in insulin self-management who are expe-
riencing hypoglycemic problems.
Continuous subcutaneous insulin infusion. The limi-
tations of long-acting insulins have driven the increasing
use of continuous subcutaneous insulin infusion (CSII) as
a realistic treatment option for many, at least in wealthy
countries. The approach is now used by over 20% of
individuals with type 1 diabetes in the U.S. (21). CSII is the
most effective generally available method of insulin deliv-
ery, although subcutaneous administration plus the con-
tinued need for frequent adjustments of infusion rates
according to intermittent self-monitoring of blood glucose
is hardly physiological. The need to justify reimbursement
of the increase in costs has resulted in a substantial
number of trials and systematic reviews. The most recent
reviews that include trials involving more modern devices
report decreases in A1C of 0.6–0.4% with no increase in
hypoglycemia, but the advantages were conﬁned to adults
with type 1 diabetes (22,23). In addition, there were
insufﬁcient data to establish beneﬁt in children and no
advantage of CSII in type 2 diabetes. Few groups have
undertaken a formal meta-analysis of hypoglycemic out-
comes due to different deﬁnitions and potential bias due to
lack of blinding when judging end points.
Observational studies report greater reductions in A1C
and severe hypoglycemia but are inevitably prone to bias
because only those who experience beneﬁt are likely to
continue using the approach. Furthermore, the use of CSII
is a complex intervention involving not only the pump but
also instruction in carbohydrate counting and insulin
adjustment within a structured training program. Thus,
part of the beneﬁt of pump therapy may relate to the
training that accompanies it. Few trials have apparently
TABLE 1
Approaches to reducing hypoglycemia in clinical practice
Preventing relative or absolute insulin excess
Y Training in insulin self-management
Y Blood glucose awareness training
Y Insulin analogs
Y Continuous subcutaneous insulin infusion
Y Pancreas transplantation
Y Islet-cell transplantation
Alerting patients to impending hypoglycemia
Y Hypoglycemia alarms utilizing continuous glucose
monitoring technology
Restoring symptoms of awareness of hypoglycemia
Y Hypoglycemia unawareness reversal programs
Augmenting glucose counterregulation
Y Indirect
Y KATP channel openers
Y Modafanil
Y Diazoxide
Y SSRIs
Y Direct
Y Alaninine
Y Terbutaline
FIG. 1. A1C and incidence of severe hypoglycemia (per patient per
preceding year) at baseline and at follow-up examinations in patients
with diabetes duration >1 year at entry following delivery of an ITTP
(N  538). Severe hypoglycemia was deﬁned as a self-reported episode
of hypoglycemia necessitating treatment with intravenous glucose or
glucagon injection. (Reproduced with permission from reference 6.)
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creases in rates of severe hypoglycemia are similar to
those reported for self-management training using multi-
ple injections.
Nevertheless, it seems clear that, for highly motivated
individuals with the ability to self-manage their diabetes
effectively, modern CSII technology can improve glycemic
control without increasing hypoglycemia. If acceptable to
the patient, it should also be part of a package for patients
experiencing problems with hypoglycemia.
Preventing insulin excess for the few, implantable
pumps and pancreas and islet transplantation. There
are a number of interventions reported to have major
effects in reducing hypoglycemia. The use of implantable
pumps housed within the subcutaneous tissue of the
abdominal wall and insulin delivered into the peritoneum
have been pioneered by a group in France. Clinical expe-
rience is relatively limited at around 350 patient-years, but
the investigators have reported major reductions in severe
hypoglycemia, impressive A1C concentrations, and im-
proved quality of life (24). Evaluation of such therapy is
largely based on observational studies, although some
randomized trials have been undertaken. Catheter block-
age is a continuing problem, and after over 15 years of
experience the approach has not entered mainstream
clinical care. It would not appear to be a realistic treat-
ment option for most adults with diabetes in the foresee-
able future.
The limitations of current insulin delivery are empha-
sized by the dramatic effect that pancreas transplantation
has in curing the problems of hypoglycemia. Whole pan-
creas transplantation leads to insulin independence in the
short and medium term and the resolution of hypoglyce-
mia unawareness at the expense of considerable periop-
erative morbidity and occasional mortality. The results of
whole pancreas transplantation have improved in recent
years, with 80% graft survival at 5 years, and it is now
approved as a treatment for severe hypoglycemic instabil-
ity (25).
Islet cell transplantation is less invasive but results in
less preservation of insulin secretion; a recent report from
specialist North American centers indicates that under
10% of recipients are insulin free at 2 years (26). Never-
theless, around 70% of individuals had detectable C-pep-
tide, of whom none were experiencing previous difﬁculties
with hypoglycemia unawareness.
Both treatments are accompanied by the hazards of
prolonged immunosuppression with increased risks of
infection and malignancy. Add to this the current shortage
of donor tissue, and it is clear that, although this treatment
has moved from an experimental to a clinical treatment in
some countries and cures even severe hypoglycemia un-
awareness, it is not an option for most individuals with
type 1 diabetes, either now or in the medium to long term.
Nevertheless, pancreas or islet transplantation should be
considered for patients with profound problems with
hypoglycemia in those areas where it is available and
when other treatments have failed.
ALERTING PATIENTS TO IMPENDING HYPOGLYCEMIA
Continuous glucose monitoring. Continuous glucose
monitoring technology has now been available for over 10
years, and each year sees further development and reﬁne-
ment; devices now on the market can provide readings in
real time and are able to alert patients to a falling glucose
level. Early studies highlighted the ability of devices to
identify unsuspected nocturnal hypoglycemia (27), but
reports of hypoglycemia in nondiabetic individuals and
disparate values registered by two similar devices at-
tached simultaneously to the same person led to a reap-
praisal of their ability to identify hypoglycemia reliably
(28). The problems are not purely technological (29). Even
if the equipment records glucose concentrations quickly
and accurately, measurements will inevitably differ due to
1) the need for calibration with blood glucose, since
failure to calibrate under steady-state conditions intro-
duces error, and 2) the physiological differences between
values measured in subcutaneous tissue (interstitial glu-
cose) and blood glucose. Thus, “real time” devices may be
of more use when providing information about the change
in glucose rather than absolute values. Continuous glucose
monitoring can identify unsuspected low glucose values,
particularly at night, which might contribute to the gener-
ation of hypoglycemia unawareness. Yet, this cannot over-
come the difﬁculty of adjusting imperfect insulin delivery
systems in an attempt to prevent insulin excess.
The real immediate potential lies in their use as a
hypoglycemia alarm, yet years after the ﬁrst introduction
of such devices, few individuals with type 1 diabetes are
using them regularly. There will always be a tradeoff
between sensitivity and speciﬁcity, but at present speciﬁc-
ity is insufﬁcient (30), perhaps in part due to differences
between interstitial and blood glucose (29). The need to
replace sensors at relatively short intervals, the greater
accuracy in the high rather than the low glucose range,
and the difﬁculty in arousing patients from sleep during
nocturnal hypoglycemic episodes emphasize the hurdles
still to be overcome. An independent group recently
concluded that none of the current devices performed
reliably enough to be recommended as hypoglycemia
alarms (31).
Observational studies have reported reductions in se-
vere hypoglycemia, but in the absence of a control group
it is unclear whether this reduction was entirely due to the
provision of the device. Randomized controlled trials have
generally shown modest advantages in surrogate end
points, such as the time spent in the normoglycemic range
(29). Whether this translates into a reduced risk of severe
hypoglycemia is unclear, as most studies are underpow-
ered due to insufﬁcient numbers of patients. A recent
systematic review found that the use of continuous mon-
itoring did not reduce A1C, but there was a suggestion that
episodes of nocturnal hypoglycemia were reduced (32).
Unfortunately, the heterogeneity of the studies, largely due
to different deﬁnitions of hypoglycemia, made it impossi-
ble to increase statistical power by pooling the data. It is
important that investigators agree to a common deﬁnition
of hypoglycemia in order to allow meta-analyses to ana-
lyze future trials.
In the absence of a reliable alarm, as Wolpert (33) has
highlighted, the potential of continuous glucose monitor-
ing to reduce hypoglycemia will depend upon the ability of
patients to combine the information obtained with the
proper adjustments to insulin and eating habits. This
requires an active interest in self-management as well as a
good working knowledge of the effects of insulin. As with
other therapeutic advances assessed in this review, the
failure to establish much effect on hypoglycemia may be
because the expert application of these practical skills is
limited to relatively few patients.
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scribed above, the development of a closed loop system in
which continuous glucose monitoring is combined with
the use of a pump controlled by an external computer has
major attractions. It would obviate the need for input from
the patient apart from ﬁlling the insulin reservoir and
replacing the sensor and its attachment. The potential for
such a device is clearly huge, although the expense will
limit uptake even within the developed world.
A detailed review of recent approaches to closed-loop
systems is available elsewhere (34). Most of the current
work focuses on devices that incorporate both subcutane-
ous glucose sensing and insulin delivery. The limitations of
subcutaneous insulin administration are less important
when blood glucose ﬂux is relatively low and challenged
during eating or exercise. Thus, much effort is focused on
overnight glucose control. Some promising early data are
emerging, and investment in the ﬁeld is now considerable,
but closed loop devices remain research tools. The devel-
opment of a practical reliable device, even for those with
hypoglycemic problems, remains years away.
RESTORING SYMPTOMS
Programs reversing hypoglycemia unawareness. The
observation that repeated episodes of short-duration mild
hypoglycemia impair sympathoadrenal and symptomatic
response to subsequent episodes and contribute to
hypoglycemia-associated autonomic failure suggests that de-
fects are functional rather than structural. The implication
that such impairment might therefore be reversible has been
established by different groups in experimental settings (35–
37). What is more relevant is how such approaches work in
clinical practice. The essential component reported by three
studies was the avoidance of all hypoglycemic episodes for a
few weeks. This required a labor-intensive approach with
frequent, often daily, contact between professional and pa-
tient and blood glucose monitoring and insulin adjustment to
prevent episodes, particularly at night (Table 2). In these
relatively short-term studies, there was no signiﬁcant deteri-
oration in glycemic control, although A1C increased in all
three. It is not clear whether reversal of unawareness can be
achieved in all patients or if such beneﬁts are sustainable. For
those who regain symptomatic awareness there is the chal-
lenging task of maintaining reasonable glycemic control
while avoiding relapse due to further hypoglycemic episodes.
One center has retested four of six patients with un-
awareness 3 years after their reversal program (38). Rela-
tively tight glycemic control had been maintained,
repeated hypoglycemia had generally been avoided, and
symptomatic responses to experimental hypoglycemia,
while lower than those measured at the end of the original
study, were higher than at baseline. However, these are
small numbers. It is noteworthy that no center appears to
have published their long-term clinical experience of man-
aging this problem, and such reports would be of consid-
erable value. Anecdotally, it is our experience, as well as
the experience of others, that some individuals ﬁnd it
impossible to alter their glucose targets and continue to be
subject to severe hypoglycemic episodes. The fact that
severe problems with hypoglycemia and unawareness
have emerged as the main clinical indication for whole
pancreas and islet transplantation also suggests that hy-
poglycemia reversal programs are limited in the degree
and duration of beneﬁt.
SPECIFIC THERAPIES TO PREVENT OR REDUCE
HYPOGLYCEMIA BY AUGMENTING COUNTERREGULATION
Caffeine/theophylline. The adenosine antagonists caf-
feine and theophylline are probably the most studied of
potential therapeutic agents to reverse or prevent hypo-
glycemia unawareness. The potential of caffeine was sug-
gested by a study that reported increased catecholamines
and symptoms during experimental hypoglycemia (39).
Based on this and other studies, the authors undertook a
3-month clinical trial in patients with type 1 diabetes and
demonstrated an increased number of symptomatic epi-
sodes, although there was no difference in asymptomatic
or severe episodes (Fig. 2) (40). A more recent study
involving relatively small numbers has reported reduced
duration of nocturnal hypoglycemia (41) as measured by
continuous glucose monitoring.
Theophylline has also been evaluated as a treatment for
hypoglycemia unawareness. Patients were recruited to a
study in which theophylline was given as an intravenous
infusion during a slow-fall hypoglycemic clamp (42). The
rise in cerebral blood ﬂow was prevented, and the thresh-
old for the increase in symptoms and epinephrine shifted
to a higher level, although there was no increase in
glucagon concentrations. The same group then studied the
effect of oral theophylline over 2 weeks and again demon-
strated increases in symptoms (although not epinephrine)
during experimental hypoglycemia (43).
While these results are of interest, the crucial question is
whether these agents protect patients from severe epi-
sodes during clinical treatment. In no study were patients
treated for an amount of time sufﬁcient to assess the effect
on hypoglycemia unawareness or rates of severe hypogly-
cemia. This is of particular relevance to these agents
because they reduce cerebral blood ﬂow. While this might
TABLE 2
Characteristics of hypoglycemia reversal programs
Y Prevention of all hypoglycemic episodes for 3–6 weeks while
keeping glycemic control unaltered
Y Frequent monitoring of blood glucose (especially at night)
Y Insulin dose and type adjustments
Y Labor-intensive process for patient and clinician
Y Lengthy process (often taking months)
FIG. 2. Total number of hypoglycemic events in 34 individuals with type
1 diabetes over 3 months. , biochemical (P  NS); f, symptomatic
(P < 0.03, caffeine vs. placebo). (Reproduced with permission from
reference 40.)
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increased vulnerability to severe episodes may in fact be
an unwanted consequence.
Modafanil. The evidence that ATP-sensitive K
 channels
(KATP channels) modulate hypothalamic sensing of hypo-
glycemia (44) and deﬁcient counterregulation (45), per-
haps through effects on -aminobutyric acid (GABA) (46),
presents other therapeutic targets. Modafanil, an agent
used in narcolepsy, reduces GABA activity most likely
through effects on K
 channels (47). The hypothesis that
inhibition of GABAminergic neurones might augment the
sympathoadrenal response has been tested in nondiabetic
subjects who received a moderate dose of modafanil or
placebo immediately before a slow-fall glucose clamp (48).
There was a modest increase in adrenergic symptoms and
protection of cognitive function but no effect on epineph-
rine levels. The authors concluded that modafanil was
worthy of further investigation, but apparently neither
they nor anyone else has since studied patients with
diabetes or hypoglycemia unawareness.
The same group has also investigated drugs that modify
KATP channels, namely gliburide (a channel closer) and
diazoxide (a channel opener) (49). Immediate delivery of
either agent to nondiabetic subjects before experimental
hypoglycemia had no effect on counterregulatory re-
sponses, although those treated with gliburide showed
some preservation of cognitive function compared with
those treated with diazoxide and those given placebo. A
further study where diazoxide was administered immedi-
ately before experimental hypoglycemia also had no effect
on sympathoadrenal responses (50). These human data
contradict the positive effect of K
 channel openers on the
hypoglycemic sympathoadrenal response observed in
rodents for reasons that are as yet unclear. Thus,
clinical potential remains uncertain and needs further
investigation.
Selective serotonin reuptake inhibitors. The use of
selective serotonin reuptake inhibitors (SSRIs) to augment
the counterregulatory response has also been explored
(51). Early reports actually associated these drugs with
hypoglycemia, but the authors reasoned that blocking
serotonin uptake might increase sympathetic outﬂow.
They demonstrated increased sympathoadrenal responses
and cortisol concentrations during experimental hypogly-
cemia in nondiabetic subjects, but symptoms were unal-
tered. These observations now need conﬁrming in diabetic
subjects and those with unawareness.
Boosting glucose counterregulation. A number of hu-
man studies in experimental settings have measured the
potential of pharmacological activation of counterregula-
tory mechanisms to boost blood glucose levels and there-
fore reduce the risk of hypoglycemia, particularly at night.
Alanine may restore deﬁcient glucagon responses in indi-
viduals with type 1 diabetes at least in part (52). Nocturnal
hypoglycemia can be prevented by oral terbutaline given
at bedtime in contrast to the relative ineffectiveness of
bedtime snacks but at the expense of a higher fasting
glucose concentration (53). The authors commented that
ﬁnding a dose that could reliably prevent nocturnal hypo-
glycemia without raising fasting glucose concentrations is
challenging (54).
It is noteworthy that, as with other potential treatments
described above, these small-scale studies that provide
proof of principle have not been followed by larger trials,
have not been adequately powered, and are of insufﬁcient
duration to measure differences in severe hypoglycemia. It
is unclear whether this gap in the literature is related to a
perception that therapies are ineffective, the difﬁculty in
securing funding, or merely the logistics in running multi-
center trials.
TYPE 2 DIABETES
It is beyond the scope of this review to evaluate speciﬁc
treatments for type 2 diabetes. Montori et al. (55) have
recently commented that there are few independently
funded trials that have addressed the effects of glucose-
lowering therapy using end points that are relevant to
patients. However, some relevant observations can be
drawn from the recent publication of the ACCORD (Action
to Control Cardiovascular Risk in Diabetes) (56) and
ADVANCE (Action in Diabetes and Vascular disease: Pre-
terax and Diamicron MR Controlled Evaluation) (57)
trials, although more detailed information regarding hypo-
glycemia will emerge shortly. The ACCORD trial utilized
an aggressive glucose control strategy with multiple oral
agents and the early use of insulin, combining both over-
night and preprandial insulin and aiming for an A1C of
6%. This produced considerable severe hypoglycemia,
which may have contributed to the adverse outcomes. In
contrast, a less aggressive approach targeting fasting glu-
cose by the stepwise addition of oral agents and eventually
overnight basal insulin produced much less severe hypo-
glycemia and weight gain with an A1C level of 6.5% (Fig. 3)
(57).
CONCLUSIONS
The virtual elimination of severe hypoglycemia in the few
patients receiving either islet or whole pancreas trans-
plants demonstrates vividly the failure of current treat-
ment to reproduce the physiology of the -cell. As we
approach 100 years of insulin therapy, many who strive for
tight glycemic control are prevented from achieving these
targets by the frequently troublesome and occasionally
devastating side effect of hypoglycemia. Data from clinical
trials indicate that insulin analogs, pumps, and continuous
glucose monitoring have generally modest effects in reduc-
ing hypoglycemic risk: those who appear to gain most
beneﬁt are those actively and skillfully engaged in their
own diabetes self-management. Reversal of hypoglycemia
unawareness, at least in part, can be achieved within
relatively short time periods and without major deteriora-
tion in glycemic control, although the long-term experi-
ence of individuals remains unclear.
FIG. 3. Absolute rates of severe hypoglycemia (% of subjects affected
during the trial) in the two glucose arms of the ACCORD and
ADVANCE trials. f, intensive control; , standard control.
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mal studies have identiﬁed potential therapeutic targets,
but early clinical trials have been unimpressive. It remains
to be seen how useful animal models of hypoglycemia will
be in identifying speciﬁc therapies to prevent or reverse
hypoglycemia. Promising pilot work in human studies
should be followed by adequately powered studies mea-
suring severe hypoglycemia. It is also important that trials,
including those sponsored by the pharmaceutical industry,
use similar deﬁnitions of hypoglycemia.
The closed-loop device trials signal a potentially excit-
ing advance, as would the availability of reliable hypogly-
cemia alarms, but the technology is currently inadequate
for the task. In the short-term, it appears that high-quality
educational/behavioral interventions offer the most cost-
effective way of enabling less hypoglycemia without
worsening glycemic control, particularly as successful
graduates of such programs appear best placed to take
advantage of technological advances.
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